Evaluation on short-term efficacy of apatinib in the palliative treatment of metastatic gastric cancer

Objective To explore the short-term efficacy of apatinib palliative treatment of metastatic gastric cancer and its impact on patients' quality of life. Methods A total of 196 patients with metastatic gastric cancer admitted to our department of oncology were randomly divided into observation group and control group. The control group received the best supportive therapy, while the observation group used apatinib palliative treatment on the basis of the control group. The disease control rate, Kappa Function Status(KPS)score and adverse reactions were compared between the two groups. Results The disease control rates of the observation group and the control group were 53.06% and 23.47%, respectively, after 2 cycles of treatment, the observation group was significantly higher than the control group(P<0.05). After treatment, the KPS score and the total effective rate of KPS in the observation group were significantly higher than those in the control group, and the difference was significant(P<0.05). Conclusion The palliative treatment of apatinib, with a higher safety, can effectively control the development of metastatic gastric cancer, significantly improve the tumor control rate and the quality of life of patients.